tbuckley/cabot-search huggingface dataset:
Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea
Authors: Juan F Masa, Jaime Corral, Candela Caballero, Emilia Barrot, Joaquin Terán-Santos, Maria L Alonso-Álvarez, Teresa Gomez-Garcia, Mónica González, Soledad López-Martín, Pilar De Lucas, José M Marin, Sergi Marti, Trinidad Díaz-Cambriles, Eusebi Chiner, Carlos Egea, Erika Miranda, Babak Mokhlesi, Estefanía García-Ledesma, M-Ángeles Sánchez-Quiroga, Estrella Ordax, Nicolás González-Mangado, Maria F Troncoso, Maria-Ángeles Martinez-Martinez, Olga Cantalejo, Elena Ojeda, Santiago J Carrizo, Begoña Gallego, Mercedes Pallero, M Antonia Ramón, Josefa Díaz-de-Atauri, Jesús Muñoz-Méndez, Cristina Senent, Jose N Sancho-Chust, Francisco J Ribas-Solís, Auxiliadora Romero, José M Benítez, Jesús Sanchez-Gómez, Rafael Golpe, Ana Santiago-Recuerda, Silvia Gomez, Mónica Bengoa
Journal: Thorax (2016)

<h3>Background</h3> Non-invasive ventilation (NIV) is an effective form of treatment in patients with obesity hypoventilation syndrome (OHS) who have concomitant severe obstructive sleep apnoea (OSA). However, there is a paucity of evidence on the efficacy of NIV in patients with OHS without severe OSA. We performed a multicentre randomised clinical trial to determine the comparative efficacy of NIV versus lifestyle modification (control group) using daytime arterial carbon dioxide tension (PaCO<sub>2</sub>) as the main outcome measure. <h3>Methods</h3> Between May 2009 and December 2014 we sequentially screened patients with OHS without severe OSA. Participants were randomised to NIV versus lifestyle modification and were followed for 2 months. Arterial blood gas parameters, clinical symptoms, health-related quality of life assessments, polysomnography, spirometry, 6-min walk distance test, blood pressure measurements and healthcare resource utilisation were evaluated. Statistical analysis was performed using intention-to-treat analysis. <h3>Results</h3> A total of 365 patients were screened of whom 58 were excluded. Severe OSA was present in 221 and the remaining 86 patients without severe OSA were randomised. NIV led to a significantly larger improvement in PaCO<sub>2</sub> of −6 (95% CI −7.7 to −4.2) mm Hg versus −2.8 (95% CI −4.3 to −1.3) mm Hg, (p&lt;0.001) and serum bicarbonate of −3.4 (95% CI −4.5 to −2.3) versus −1 (95% CI −1.7 to −0.2 95% CI) mmol/L (p&lt;0.001). PaCO<sub>2</sub> change adjusted for NIV compliance did not further improve the inter-group statistical significance. Sleepiness, some health-related quality of life assessments and polysomnographic parameters improved significantly more with NIV than with lifestyle modification. Additionally, there was a tendency towards lower healthcare resource utilisation in the NIV group. <h3>Conclusions</h3> NIV is more effective than lifestyle modification in improving daytime PaCO<sub>2</sub>, sleepiness and polysomnographic parameters. Long-term prospective studies are necessary to determine whether NIV reduces healthcare resource utilisation, cardiovascular events and mortality. <h3>Trial registration number</h3> NCT01405976; results.
Bicyclist's vulva: observational study * Commentary: Attitudes to women's bicycling have changed
Authors: L. Baeyens
Journal: BMJ (2002)

Many chronic injuries related to athletic bicycling are now recognised: cyclist's nipples, 1 neuropathic syndromes, 2 and skin problems caused by the saddle.We have seen a new clinical problem in female high level cycling competitors: bicyclist's vulva (figure).
Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
Authors: Geir Mjøen, Hallvard Holdaas
Journal: New England Journal of Medicine (2016)

To the Editor: Grams et al. (Feb.4 issue) 1 quantified the associations between "13 distinct demographic and health characteristics" and end-stage renal disease among low-risk members of seven general population cohorts in order to estimate the long-term risk of end-stage renal disease among kidney-donor candidates.Two important factors were not considered: biologic and household relatedness to a person with end-stage renal disease.Most living kidney donors are genetically related to their recipients, and heredity is a known contributor to kidney disease. 2 Furthermore, many related donors and their recipients grow up following similar dietary, exercise, and other health-related practices, factors that also affect the incidence of end-stage renal disease. [3]][5] Grams et al. acknowledge the importance of genetic and environmental influences when they note that these influences may have contributed to the variation in risk associated with race uncovered in their study.The failure to incorporate these two factors into their equations renders the authors' estimates of the risk of end-stage renal disease suspect at best.
Case 39-1982
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, G. M. Pohost, T. H. Aretz
Journal: New England Journal of Medicine (1982)

Presentation of CaseA 59-year-old man was admitted to the hospital because of delirium and dyspnea.He was well until 10 months earlier, when there was the abrupt onset of dyspnea at rest as well as on exertion. He was admitted to another hospital, where an x-ray film of the chest revealed evidence of congestive heart failure. The pulmonary-capillary wedge pressure was 18 mm Hg and fell to 14 mm Hg after the administration of a diuretic medication, but repeated x-ray films of the chest revealed no change. An echocardiogram disclosed no evidence of valvular disease or an atrial myxoma. . . .
Patient-Centered Outcomes Research—Opportunities for Novel, Innovative, and Transformative Partnerships With Patients and Their Families
Authors: Rebecca A. Aslakson, Matthew Weiss
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
ENVIRONMENTAL FACTORS IN ISCHEMIC HEART DISEASE
Authors: L E FARHI
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells
Authors: Julie A. Reisz, Matthew J. Wither, Monika Dzieciatkowska, Travis Nemkov, Aaron Issaian, Tatsuro Yoshida, Andrew J. Dunham, Ryan C. Hill, Kirk C. Hansen, Angelo D’Alessandro
Journal: Blood (2016)
Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML)
Authors: Anna Dolnik, Sundaram R. Chakkarappan, Tamara J. Blätte, Sibylle Cocciardi, Jan Krönke, Corbacioglu Andrea, Karlheinz Holzmann, Peter Paschka, Frank G. Rücker, Silke Kapp-Schwoerer, Verena I. Gaidzik, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner, Lars Bullinger
Journal: Blood (2015)
Allogeneic T Cells Utilize Glycolysis As the Predominant Metabolic Pathway to Induce Acute Graft-Versus-Host Disease
Authors: Hung Nguyen, Kelley MK Haarberg, Yongxia Wu, Jianing Fu, Jessica Lauren Heinrichs, David Bastian, Steven Schutt, Sharad Shrestha, Chen Lui, Hongbo Chi, Xue-Zhong Yu
Journal: Blood (2014)
Book: Management of Acute and Chronic Pain
Authors: M. Zacharias
Journal: BMJ (1999)

Ed Narinder Rawal BMJ Books, £25, pp 240 ISBN 0 7279 1193 7 Rating: ![Graphic][1]</img>![Graphic][2]</img>![Graphic][3]</img> In the past two decades we have seen a thorough change in the medical profession's attitude towards pain and its control. Recent publications on pain suggest the growing demand for information. To study the mechanisms we … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif [3]: /embed/inline-graphic-3.gif
Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
Authors: Jun Young Kim, Dong Hyun Sinn, Geum-Youn Gwak, Gyu-Seong Choi, Aldosri Meshal Saleh, Jae-Won Joh, Sung Ki Cho, Sung Wook Shin, Keumhee Chough Carriere, Joong Hyun Ahn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Journal: Clinical and Molecular Hepatology (2016)

Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality.In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed.The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decisiontree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1-B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by 'oligo' (2-4) nodules of intermediate size (5-10 cm) when the AFP levels was <400 ng/ml, or 'oligo' (2-4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3).SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.
Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK<sub>1</sub> receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
Authors: Matti S. Aapro, Giorgia Rossi, Giada Rizzi, Maria Elisa Borroni, Norman G. Nagl
Journal: Journal of Clinical Oncology (2013)

66 Background: Certain antiemesis guidelines recommend combining a 5-HT 3 RA, a NK 1 RA and DEX for prevention of CINV associated with highly emetogenic chemotherapy (HEC) and with anthracycline + cyclophosphamide (AC)-based MEC. The objective of this analysis was to determine if using the oral fixed-dose combination NEPA prior to initiating AC-based chemotherapy resulted in no impact on daily living (NIDL) for patients. Methods: This phase III, multinational, randomized, double-blind, double-dummy, active-controlled, parallel group trial enrolled patients with solid tumors who were naïve to cytotoxics and scheduled to initiate AC-based chemotherapy. Patients received oral NEPA (netupitant 300 mg + PALO 0.5 mg) + oral DEX 12 mg on Day 1, or oral PALO 0.5 mg + oral DEX 20 mg on Day 1. The primary efficacy endpoint was Complete Response (CR: no emesis/no rescue medication) in the delayed phase (25-120 hours after chemotherapy) in cycle 1. Secondary endpoints including NIDL for patients was assessed using the Functional Living Index—Emesis (FLIE) during the first 120 hours. Results: 1,455 patients were randomized; 1,449 were included in the efficacy analysis. Significantly more patients achieved CR during the delayed phase in the NEPA arm compared with the PALO arm (76.9% vs 69.5%, respectively: p = 0.001). Significantly more patients in the NEPA arm reported NIDL via the FLIE (78.5% vs 72.1%: p = 0.005). A greater proportion of NEPA-treated patients reported no personal hardship imposed and no daily functioning affected (75.3% vs 70.5% and 77.1% vs 71.6%, respectively, as scored by the nausea domain of the FLIE; 95.2% vs 89.2% and 95.6% vs 89.2%, respectively, as scored by the vomiting domain of the FLIE). Adverse events were similar for both groups. Conclusions: NEPA significantly improved efficacy vs PALO for prevention of CINV in AC MEC and significantly more patients experienced NIDL compared to PALO. Both regimens were generally well tolerated.
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial
Authors: Gerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, Gerlinde Egerer, Monika Lamprecht, Ulrich Keller, Hans-Heinrich Wolf, Carsten Hirt, Stephan Stilgenbauer, Mascha Binder, Peter Hau, Matthias Edinger, Norbert Frickhofen, Martin Bentz, Robert Möhle, Alexander Röth, Michael Pfreundschuh, Louisa von Baumgarten, Martina Deckert, Claudia Hader, Heidi Fricker, Elke Valk, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke
Journal: The Lancet Haematology (2016)
Toward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design
Authors: Hallie C. Prescott, Carolyn S. Calfee, B. Taylor Thompson, Derek C. Angus, Vincent X. Liu
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<Why Lump?Why Split?Potential SolutionsChallenges and Limitation...ConclusionsReferencesCITING ARTICLES
Response to: ‘Does the prevalence of radiographic hand osteoarthritis in patients with HIV-1 infection increase or not?’ by Luo<i>et al</i>
Authors: Jérémie Sellam, Karine Lacombe, Anne-Laurence Tomi, Ida K Haugen, David T Felson, Soraya Fellahi, Jean-Philippe Bastard, Anne Miquel, Manuela Sebire, Caroline Rey-Jouvin, Emmanuel Maheu, Jacqueline Capeau, Pierre-Marie Girard, Jean-Luc Meynard, Francis Berenbaum
Journal: Annals of the Rheumatic Diseases (2016)

We thank Luo et al 1 for their interest in our work demonstrating for the first time that patients with HIV-1 infection display radiographic hand osteoarthritis (HOA) more frequently than the general population and that metabolic syndrome (MetS) is an independent factor associated with HOA presence and severity in the setting of HIV-1 infection.2 We would like to respond point-to-point to each comment.

Not all confounding factors, such as genetic factors, have been taken into account when we compared the prevalence radiographic HOA between the Framingham and the Metabolic Syndrome and Fibrosis-Osteoarthritis (METAFIB-OA) cohorts as well as between patients with HIV-1 infection w/o MetS in the METAFIB-OA cohort. However, a major purpose of our study was to compare the prevalence of HOA in patients who had HIV-1 infection with that from the Framingham cohort. The Framingham Study has been used as a group representative of the general population in many previous studies including in recent lupus studies. …
Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review
Authors: Laura Folgori, Julia Bielicki, Beatriz Ruiz, Mark A Turner, John S Bradley, Daniel K Benjamin, Theoklis E Zaoutis, Irja Lutsar, Carlo Giaquinto, Paolo Rossi, Mike Sharland
Journal: The Lancet Infectious Diseases (2016)
Case 50-1989
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Robert G. Zwerdling, Eugene J. Mark
Journal: New England Journal of Medicine (1989)

Presentation of CaseA 17-year-old boy was admitted to the hospital because of pneumonitis of the right lower lobe.The patient was in a stable state of health until one week earlier, when a cough developed that was productive of yellow sputum that soon became clear. Five days before entry the patient noticed a few flecks of blood in his sputum. During the two days before admission increasing amounts of blood appeared in the sputum, and frank chills occurred; his temperature rose as high as 40°C; right-sided pleuritic pain developed and was aggravated by coughing. One day before admission the . . .
Improving the accuracy of sports medicine surveillance: when is a subsequent event a new injury?
Authors: Ian Shrier, Ben Clarsen, Evert Verhagen, Kerry Gordon, Jay Mellette
Journal: British Journal of Sports Medicine (2016)

The recent increased use of injury and illness surveillance programmes has the potential to greatly advance our knowledge about risk factors and treatment effectiveness. Maximising this potential requires that data be entered in a format that can be interpreted and analysed. One remaining challenge concerns whether and when an increase in symptoms should be documented within an existing injury record (eg, exacerbation) versus a new injury record. In this review, we address this challenge using the principles of the multistate framework for the analysis of subsequent injury in sport (M-FASIS). In brief, we argue that a new injury record should be documented whenever there is an increase in symptoms due to activity-related exposures that is beyond the normal day-to-day symptom fluctuations, regardless of whether the athlete was in a ‘healthy state’ immediately before the event. We illustrate the concepts with concrete examples of shoulder osteoarthritis, ankle sprains and ACL tears.
The Toddler's Fracture—A Common, Obscure Fracture of the Tibia
Authors: S A GLADSTONE
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EPHB4 kinase–inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis
Authors: Silvia Martin-Almedina, Ines Martinez-Corral, Rita Holdhus, Andres Vicente, Elisavet Fotiou, Shin Lin, Kjell Petersen, Michael A. Simpson, Alexander Hoischen, Christian Gilissen, Heather Jeffery, Giles Atton, Christina Karapouliou, Glen Brice, Kristiana Gordon, John W. Wiseman, Marianne Wedin, Stanley G. Rockson, Steve Jeffery, Peter S. Mortimer, Michael P. Snyder, Siren Berland, Sahar Mansour, Taija Makinen, Pia Ostergaard
Journal: Journal of Clinical Investigation (2016)

Hydrops fetalis describes fluid accumulation in at least 2 fetal compartments, including abdominal cavities, pleura, and pericardium, or in body tissue. The majority of hydrops fetalis cases are nonimmune conditions that present with generalized edema of the fetus, and approximately 15% of these nonimmune cases result from a lymphatic abnormality. Here, we have identified an autosomal dominant, inherited form of lymphatic-related (nonimmune) hydrops fetalis (LRHF). Independent exome sequencing projects on 2 families with a history of in utero and neonatal deaths associated with nonimmune hydrops fetalis uncovered 2 heterozygous missense variants in the gene encoding Eph receptor B4 (EPHB4). Biochemical analysis determined that the mutant EPHB4 proteins are devoid of tyrosine kinase activity, indicating that loss of EPHB4 signaling contributes to LRHF pathogenesis. Further, inactivation of Ephb4 in lymphatic endothelial cells of developing mouse embryos led to defective lymphovenous valve formation and consequent subcutaneous edema. Together, these findings identify EPHB4 as a critical regulator of early lymphatic vascular development and demonstrate that mutations in the gene can cause an autosomal dominant form of LRHF that is associated with a high mortality rate.
The prevalence of mitral valve prolapse in patients with panic disorders
Authors: R Liberthson, D V Sheehan, M E King, A E Weyman
Journal: American Journal of Psychiatry (1986)

Of 131 patients with panic disorder or agoraphobia, 44 (34%) had definite mitral valve prolapse on the basis of clinical findings of an apical mid- or late systolic click and a murmur and/or a two-dimensional echocardiogram showing prolapse of one leaflet in two views or of two leaflets in a single view. Seven other patients (5%) had a probable diagnosis of mitral prolapse on the basis of a typical murmur alone or an intermittent apical mid- or late systolic click and a prolapsing leaflet in a single echocardiographic view. This finding confirms previous reports of the association between panic disorder and mitral valve prolapse.
In rectal carcinoma, colostomy or no colostomy: is this the question?
Authors: J A Ajani
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.1.193 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8418233 In rectal carcinoma, colostomy or no colostomy: is this the question? J A AjanixJ A AjaniSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.1.193 PDF "In rectal carcinoma, colostomy or no colostomy: is this the question?." Journal of Clinical Oncology, 11(1), pp. 193–194© 1993 by American Society of Clinical Oncology